The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases

Table 3

Recommended interventions by disease area.

Disease area	IHD	NSCLC	COPD	AD	T2D	Total
Pharmacotherapies	28	61	40	6	11	146
Behavioral/lifestyle modifications	10	1	2	0	8	21
Surgical interventions	2	4	0	0	0	6
Other interventions	2	3	5	1	0	11
Total discrete interventions	42	69	47	7	19	184

IHD = ischemic heart disease; NSCLC = non-small cell lung cancer; COPD = chronic obstructive pulmonary disease; AD = Alzheimer’s disease; T2D = type 2 diabetes.